Latest Regulatory Approvals News

Silver Mines Limited is progressing its Bowdens Silver Project development application with updated ecological surveys, while exploration intensifies at the Rockwell Prospect and Californian assets, supported by a solid cash position.

Actinogen Medical’s pivotal XanaMIA trial clears a key interim hurdle with the Data Monitoring Committee endorsing continuation, while a $16.8 million capital raise and non-dilutive funding bolster its balance sheet ahead of final results due November 2026.

Zeotech pushed forward its AusPozz™ metakaolin commercialisation with extended and new MOUs, progressed key Toondoon project approvals amid rising contractor costs, and launched live methane control trials.

Bannerman Energy has locked in a landmark US$321.5 million strategic investment from CNNC Overseas Limited, enabling debt-free construction of its Etango Uranium Project and setting the stage for a Final Investment Decision in H2 2026.

Southern Palladium reported a doubling in chromite recoveries at its Bengwenyama project, prompting a redesign of the processing plant and pushing the DFS completion to late Q4 2026 amid drilling delays and enhanced metallurgical work.

Emyria Limited is extending its Empax mental health clinic network into New South Wales through a new partnership with Matilda Nepean Private Hospital, increasing treatment capacity and national reach ahead of a planned Q3 2026 launch.

Redcastle Resources completes a 13,539m grade control drilling program at Redcastle Reef, delivering exceptional high-grade gold intercepts and identifying a 300m western extension. Sixteen new gold targets emerge across the underexplored TBone Belt as mine readiness progresses toward mid-2026 production.

TrivarX appoints Dr Danielle Meyrick as CEO to spearhead clinical trials and commercialisation of its novel stable isotope MRI brain cancer imaging platform, with Phase 1 studies on track for completion this year.

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.

Alcidion Group delivered positive cashflow and strong new sales in Q3 FY26, with contract expansions in the UK and Australia. The company remains on track for a significant Electronic Patient Record contract signing in May.

Ardea Resources is progressing its Kalgoorlie Nickel Project’s Definitive Feasibility Study with strong financial and strategic support from a Japanese Consortium and government export banks, aiming to secure a major nickel-cobalt supply chain.

Argenica Therapeutics is progressing its ARG-007 drug toward a targeted Phase 2b trial for acute ischaemic stroke, leveraging AI for patient selection and securing key regulatory approvals, while maintaining a solid cash position of $8 million.